Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.52 |
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009537 | 0.94 | MALT1 (0.48) | CACNA1GMALT1DRD2DRD4 | |
| SCHEMBL4249382 | 0.94 | CACNA1G (0.48) | CACNA1GDRD2 | |
| SCHEMBL13994809 | 0.93 | CACNA1G (0.48) | CACNA1GMALT1DRD2DRD4 | |
| SCHEMBL4248009 | 0.89 | CACNA1G (0.43) | CACNA1GMALT1DRD2DRD4 | |
| SCHEMBL5011452 | 0.87 | CACNA1G (0.45) | CACNA1GMALT1DRD2DRD4 | |
| SCHEMBL5009526 | 0.87 | DRD2 (0.53) | CACNA1GDRD2DRD4DRD3 | |
| SCHEMBL4245577 | 0.86 | HTR1A (0.48) | DRD2DRD4DRD3 | |
| SCHEMBL4253374 | 0.85 | MALT1 (0.48) | CACNA1GMALT1DRD2DRD4DRD3 | |
| SCHEMBL4250460 | 0.85 | MALT1 (0.47) | CACNA1GMALT1DRD2DRD4DRD3 | |
| SCHEMBL3228411 | 0.84 | SIGMAR1 (0.58) | DRD2DRD4SLC16A3SLC16A1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312253-A1 | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | US | claimed |
| US-20080312253-A1 | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312253-A1 | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312253-A1 | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312253-A1 | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | HTR3A, HTR3B, HTR3E | CACNA1G 1316/4885MALT1 733/4885DRD2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.